Merz Pharmaceuticals has launched Xeomin (incobotulinumtoxinA) for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously treated patients and blepharospasm in adults previously treated with onabotulinumtoxinA. Xeomin is a botulinum toxin type A that is free from accessory proteins.

Xeomin is available in 50-unit and 100-unit vials.

For more information call (888) 4-XEOMIN or visit www.xeomin.com.